《科创板日报》9月19日讯(记者 史士云)日前,轩竹生物科技股份有限公司 (以下简称:轩竹生物)通过港交所主板上市聆讯,即将在港股上市,中金公司为其独家保荐人。轩竹生物曾在2022年9月向科创板递交招股书,计划募资24.7亿元,然而,经两轮问询和暂缓审议后,轩竹生物于2024年5月主动撤回了IPO申请。轩竹生物的控股股东为港股上市公司四环医药(00460.HK),在科创板上市进程终止后,四环医药...
Source Link《科创板日报》9月19日讯(记者 史士云)日前,轩竹生物科技股份有限公司 (以下简称:轩竹生物)通过港交所主板上市聆讯,即将在港股上市,中金公司为其独家保荐人。轩竹生物曾在2022年9月向科创板递交招股书,计划募资24.7亿元,然而,经两轮问询和暂缓审议后,轩竹生物于2024年5月主动撤回了IPO申请。轩竹生物的控股股东为港股上市公司四环医药(00460.HK),在科创板上市进程终止后,四环医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.